These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Some aspects of the clinical use of lercamen (lercadipine)].
    Author: Kavtaradze GV, Kostava MT, Gvetadze LG.
    Journal: Georgian Med News; 2009; (172-173):50-3. PubMed ID: 19644190.
    Abstract:
    The paper deals with the comparative study of the effects of lercamen (lercadipine) and amlodipine, two third-generation long-acting calcium channel blocker medicine of the dihydropyridine type used in the treatment of hypertension. 80 patients of both sexes, aged from 48 to 76 were treated with lercamen (10-20 mg) or amlodipine (10 mg) for twelve weeks. Some adverse reactions of the above mentioned drugs such as headache, ankle oedema and others were observed and studied with great care. A two-week treatment with lercamen (10 mg) resulted in significant decrease of both systolic and diastolic blood pressure in 74% patients. Further decrease of blood pressure was observed during the following 10 weeks. The doze of lercamen had to be doubled for 26% of patients. After 12 weeks blood pressure in lercamen group was 126+/-4.5/80.4+/-5.3 mmHg (p<0.01 versus baseline). Amlodipine caused similar decrease of blood pressure. Sympathetic activation occurs neither with lecramene not with amlodipine during chronic therapy. Less adverse drug reactions were observed among lercamen group, which equaled with 12% than among the amlodipine group, which was 26,3%. We believe that adverse reactions are weakly expressed in lercamen group than in amlodipine group due to high lypophility and unique membrane kinetic of lercamen. Lercamen has proved not only better efficiency but also better endurance in chronic treatment of essential hypertension in patients.
    [Abstract] [Full Text] [Related] [New Search]